Sedana Medical Valuation

Q: What is the Fair Price of SEDANA when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

SEDANA (SEK22.15) is trading below our estimate of [[fair value]] (SEK126.9)

Is SEDANA undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

3/6

Valuation Score 3/6

Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of SEDANA when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: SEDANA (SEK22.15) is trading below our estimate of fair value (SEK126.9)

Significantly Below Fair Value: SEDANA is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for SEDANA?

Other financial metrics that can be useful for relative valuation.

The above table shows the n/a ratio for SEDANA. This is calculated by dividing SEDANA's market cap by their current preferred multiple.
What is SEDANA's n/a Ratio?
n/a	0x
n/a	n/a
Market Cap	SEK 2.20b

SEDANA key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	11.3x
Enterprise Value/EBITDA	-34.9x
PEG Ratio	n/a

Price to Sales Ratio vs Peers

How does SEDANA's PS Ratio compare to its peers?

The above table shows the PS ratio for SEDANA vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PS	Estimated Growth	Market Cap
Peer Average	4.2x
STIL Stille	4.9x	17.0%	SEK 2.1b
CRAD B C-Rad	2.9x	13.0%	SEK 1.4b
CARE Careium	1x	10.4%	SEK 817.4m
CEVI CellaVision	8.1x	13.6%	SEK 5.9b
SEDANA Sedana Medical	13x	38.3%	SEK 2.2b

Price-To-Sales vs Peers: SEDANA is expensive based on its Price-To-Sales Ratio (13x) compared to the peer average (4.2x).

Price to Earnings Ratio vs Industry

How does SEDANA's PE Ratio compare vs other companies in the SE Medical Equipment Industry?

0 Companies	Price / Earnings	Estimated Growth	Market Cap
Industry Avg.	n/a	24.7%
	n/a	n/a	n/a

Fetching data

0 Companies	Price / Earnings	Estimated Growth	Market Cap
Industry Avg.	n/a	24.7%
	n/a	n/a	n/a

No more companies

Price-To-Sales vs Industry: SEDANA is expensive based on its Price-To-Sales Ratio (13x) compared to the Swedish Medical Equipment industry average (5.2x).

Price to Sales Ratio vs Fair Ratio

What is SEDANA's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

SEDANA PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio	13x
Fair PS Ratio	13.4x

Price-To-Sales vs Fair Ratio: SEDANA is good value based on its Price-To-Sales Ratio (13x) compared to the estimated Fair Price-To-Sales Ratio (13.4x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst SEDANA forecast and predictions for the stock price in 12 month’s time.
Date	Share Price	Average 1Y Price Target	Dispersion	High	Low	1Y Actual price	Analysts
Current	SEK 22.15	SEK 36.00 +62.5%	19.4%	SEK 43.00	SEK 29.00	n/a	2
Jul ’25	SEK 23.30	SEK 35.50 +52.4%	21.1%	SEK 43.00	SEK 28.00	n/a	2
Jun ’25	SEK 27.00	SEK 35.50 +31.5%	21.1%	SEK 43.00	SEK 28.00	n/a	2
May ’25	SEK 22.65	SEK 35.50 +56.7%	21.1%	SEK 43.00	SEK 28.00	n/a	2
Apr ’25	SEK 16.01	SEK 35.50 +121.7%	29.6%	SEK 46.00	SEK 25.00	n/a	2
Mar ’25	SEK 17.52	SEK 35.50 +102.6%	29.6%	SEK 46.00	SEK 25.00	n/a	2
Feb ’25	SEK 20.54	SEK 43.00 +109.3%	7.0%	SEK 46.00	SEK 40.00	n/a	2
Jan ’25	SEK 23.16	SEK 43.00 +85.7%	7.0%	SEK 46.00	SEK 40.00	n/a	2
Dec ’24	SEK 20.70	SEK 43.00 +107.7%	7.0%	SEK 46.00	SEK 40.00	n/a	2
Nov ’24	SEK 19.27	SEK 43.00 +123.1%	7.0%	SEK 46.00	SEK 40.00	n/a	2
Oct ’24	SEK 18.83	SEK 58.00 +208.0%	13.8%	SEK 66.00	SEK 50.00	n/a	2
Sep ’24	SEK 19.35	SEK 58.00 +199.7%	13.8%	SEK 66.00	SEK 50.00	n/a	2
Aug ’24	SEK 23.24	SEK 64.00 +175.4%	21.9%	SEK 78.00	SEK 50.00	SEK 22.85	2
Jul ’24	SEK 27.04	SEK 69.00 +155.2%	27.5%	SEK 88.00	SEK 50.00	SEK 23.30	2
Jun ’24	SEK 29.48	SEK 69.00 +134.1%	27.5%	SEK 88.00	SEK 50.00	SEK 27.00	2
May ’24	SEK 25.76	SEK 69.00 +167.9%	27.5%	SEK 88.00	SEK 50.00	SEK 22.65	2
Apr ’24	SEK 21.38	SEK 70.00 +227.4%	28.6%	SEK 90.00	SEK 50.00	SEK 16.01	2
Mar ’24	SEK 22.50	SEK 70.00 +211.1%	28.6%	SEK 90.00	SEK 50.00	SEK 17.52	2
Feb ’24	SEK 22.66	SEK 72.00 +217.7%	30.6%	SEK 94.00	SEK 50.00	SEK 20.54	2
Jan ’24	SEK 18.70	SEK 72.00 +285.0%	30.6%	SEK 94.00	SEK 50.00	SEK 23.16	2
Dec ’23	SEK 18.45	SEK 72.00 +290.2%	30.6%	SEK 94.00	SEK 50.00	SEK 20.70	2
Nov ’23	SEK 20.30	SEK 72.00 +254.7%	30.6%	SEK 94.00	SEK 50.00	SEK 19.27	2
Oct ’23	SEK 24.46	SEK 75.50 +208.7%	33.8%	SEK 101.00	SEK 50.00	SEK 18.83	2
Sep ’23	SEK 24.50	SEK 75.50 +208.2%	33.8%	SEK 101.00	SEK 50.00	SEK 19.35	2
Aug ’23	SEK 27.32	SEK 75.50 +176.4%	33.8%	SEK 101.00	SEK 50.00	SEK 23.24	2

Analyst Forecast: Target price is more than 20% higher than the current share price, but there are not enough analysts covering the stock to determine statistical confidence in agreement.